- Home
- SNES vs CERO Comparison
SNES vs CERO Comparison
Compare SNES & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- CERO
- Stock Information
- Founded
- SNES 2004
- CERO 2017
- Country
- SNES United States
- CERO United States
- Employees
- SNES N/A
- CERO N/A
- Industry
- SNES Agricultural Chemicals
- CERO
- Sector
- SNES Industrials
- CERO
- Exchange
- SNES Nasdaq
- CERO Nasdaq
- Market Cap
- SNES 2.9M
- CERO 3.1M
- IPO Year
- SNES 2016
- CERO N/A
- Fundamental
- Price
- SNES $1.95
- CERO $0.62
- Analyst Decision
- SNES Strong Buy
- CERO
- Analyst Count
- SNES 1
- CERO 0
- Target Price
- SNES $10.00
- CERO N/A
- AVG Volume (30 Days)
- SNES 37.9K
- CERO 963.3K
- Earning Date
- SNES 05-08-2025
- CERO 05-16-2025
- Dividend Yield
- SNES N/A
- CERO N/A
- EPS Growth
- SNES N/A
- CERO N/A
- EPS
- SNES N/A
- CERO N/A
- Revenue
- SNES $1,857,000.00
- CERO N/A
- Revenue This Year
- SNES $130.53
- CERO N/A
- Revenue Next Year
- SNES $80.00
- CERO N/A
- P/E Ratio
- SNES N/A
- CERO N/A
- Revenue Growth
- SNES 55.66
- CERO N/A
- 52 Week Low
- SNES $1.30
- CERO $0.53
- 52 Week High
- SNES $9.80
- CERO $172.00
- Technical
- Relative Strength Index (RSI)
- SNES 49.49
- CERO 30.38
- Support Level
- SNES $1.30
- CERO $0.53
- Resistance Level
- SNES $1.75
- CERO $0.84
- Average True Range (ATR)
- SNES 0.20
- CERO 0.10
- MACD
- SNES 0.07
- CERO 0.03
- Stochastic Oscillator
- SNES 75.58
- CERO 23.31
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.